Skip to content
BiologicalX

Comparison

TUDCA vs Vitamin D3 + K2

Side-by-side of TUDCA and Vitamin D3 + K2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

TUDCA

  • Bile-acid molecule (taurine-conjugated UDCA) with chemical chaperone activity at the endoplasmic reticulum
  • Established pharmaceutical use for cholestasis and primary biliary cholangitis at 500-750 mg/day
  • Reduces ER stress and stabilizes misfolded proteins; the mechanistic basis for emerging ALS / retinal applications
  • Modest improvements in NAFLD markers and insulin sensitivity at 500-1,750 mg/day in small trials
  • Mitochondrial protection signal in animal models drives the longevity-supplement positioning
  • Generally well-tolerated; mild GI effects are the main dose-dependent issue

Vitamin D3 + K2

  • Reduces non-vertebral fractures 10-20% in older adults at 800 IU/day or above when combined with calcium
  • VITAL trial showed neutral results on primary CV and cancer endpoints at 2000 IU/day over 5 years
  • Vitamin D supplementation reduces respiratory infection incidence ~10-20% in deficient populations
  • K2 MK-7 has 72-hour plasma half-life vs 1-2 hours for MK-4; once-daily dosing is sufficient
  • Synergy hypothesis is largely preclinical; dedicated combination RCTs are limited
  • Daily dosing outperforms bolus dosing for immune and infection outcomes

Side-by-side

Attribute TUDCA Vitamin D3 + K2
Category supplement supplement
Also known as tauroursodeoxycholic acid, taurine-conjugated UDCA cholecalciferol + menaquinone, D3/K2, vitamin D3 with MK-7
Half-life (hr) 4 360
Typical dose (mg) 500 0.05
Dosing frequency daily, divided into 2 doses with food daily with a fat-containing meal
Routes oral oral
Onset (hr) 1 24
Peak (hr) 2 168
Molecular weight 499.7 384.64
Molecular formula C26H45NO6S C27H44O (D3); C46H64O2 (MK-7)
Mechanism Bile-acid signaling via FXR/TGR5 receptors; chemical chaperone reducing ER stress and unfolded protein response; mitochondrial protection through reduced outer-membrane permeabilization. D3 converts to calcidiol then calcitriol, activating the vitamin D receptor (VDR) to increase intestinal calcium absorption and modulate immune and bone gene transcription. K2 carboxylates osteocalcin and matrix Gla protein, directing calcium toward bone and inhibiting vascular calcification.
Legal status OTC dietary supplement (US); pharmaceutical in Italy and several Asian countries Dietary supplement (global)
WADA status allowed allowed
DEA / Rx OTC supplement Not scheduled
Pregnancy Insufficient data for supplement use; UDCA used in cholestasis of pregnancy Recommended at standard doses for fetal bone development; consult clinician at higher doses
CAS 14605-22-2 67-97-0
PubChem CID 9848818 5280795
Wikidata Q418751 Q139347

Safety profile

TUDCA

Common side effects

  • mild GI upset
  • diarrhea (dose-dependent)
  • constipation (rare)
  • nausea

Contraindications

  • complete biliary obstruction
  • pregnancy / lactation (insufficient supplement-dose data)
  • active GI disease without medical supervision

Interactions

  • cyclosporine, oral contraceptives, fat-soluble vitamins: modest absorption changes via altered bile-acid pool(minor)
  • phenylbutyrate: synergistic for ALS use (Relyvrio combination); consult clinician(moderate)

Vitamin D3 + K2

Common side effects

  • GI upset at high doses
  • headache (rare)
  • hypercalcemia (only at sustained very high D3 doses)

Contraindications

  • hypercalcemia
  • sarcoidosis
  • active hyperparathyroidism
  • warfarin therapy (K2 component requires stable intake)

Interactions

  • warfarin: K2 component can affect anticoagulation; maintain stable intake and inform anticoagulation clinic(moderate)
  • thiazide diuretics: additive calcium retention; hypercalcemia risk with high-dose D3(moderate)
  • digoxin and calcium channel blockers: additive effects from D3-induced hypercalcemia(moderate)
  • glucocorticoids: reduced vitamin D efficacy and bone effects(moderate)
  • cholestyramine and orlistat: bind fat-soluble vitamins; separate dosing by 2 to 4 hours(moderate)

Which Should You Take?

TUDCA and Vitamin D3 + K2 score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.

  • If your priority is liver function, pick TUDCA.
  • If your priority is mitochondrial function, pick TUDCA.
  • If your priority is bone density, pick Vitamin D3 + K2.
  • If your priority is cardiovascular health, pick Vitamin D3 + K2.

Edge case: Half-lives differ materially (TUDCA ~4 hr vs Vitamin D3 + K2 ~360 hr). Vitamin D3 + K2 reaches steady state faster; TUDCA is easier to dial in if tolerability is uncertain.

Default choice: either is defensible. TUDCA edges out on goal breadth + legal accessibility; Vitamin D3 + K2 is the right call if your priority sits in the goals listed above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between TUDCA and Vitamin D3 + K2?

TUDCA and Vitamin D3 + K2 differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, TUDCA or Vitamin D3 + K2?

TUDCA half-life is 4 hours; Vitamin D3 + K2 half-life is 360 hours.

Can you stack TUDCA with Vitamin D3 + K2?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper